Not Much Difference in Efficacy, Safety between 2 PCSK9 Inhibitors: Dr Teramoto of Teikyo University

Prof. Tamio Teramoto There is not much difference in the efficacy and safety of the two PCSK9 inhibitors including Praluent (alirocumab), which are approved in Japan, said Tamio Teramoto, professor at Teikyo University, at a press seminar held by Sanofi...read more